^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BL-22

    i
    Associations
    News

    Trials

    Company:
    AstraZeneca
    Drug class:
    CD22 inhibitor, Immunotoxin
    Related drugs:
    Associations
    News

    Trials

    Apply
    BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (NCT00024115)
    Phase 1
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    04/28/2015
    CD22
    |
    BL-22